Replies to post #35071 on NorthWest Biotherapeutics Inc (NWBO)

[Truthfan]

Correct me if I'm wrong; however, isn't Dr. Coukos now with the Ludwig Centre at Lausanne (Switzerland) wherein a number of clinical trials for ovarian cancer are taking place - including DC Vax.

The following from the Ludwig Centre's website:

A phase I/II trial of DCVax, being developed by Northwest Biotherapeutics, in patients with solid tumors (NCT01882946) - See more at: http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/ovarian-cancer#sthash.tm5WBrvE.dpuf

[sentiment_stocks]

Interesting Koman... thanks. :)

Dr. George Coukos who headed the pI trial in Ovarian Cancer using DCVAX-L and was supposed to do a pII trial left UPENN to head up a lab in EU.

[obuhz]

"Now I think I know why the NWBO- UPENN collaboration on Ovarian cancer evaporated. "

Or maybe NWBO just did not have enough money to proceed to a P2 trial as the P1 ended somewhat in 2009. At that time, the company had to stop the GBM trial for 2 years.

"I'm assuming if there was some significant results it would have been published but just as I expected that dc vaccines by itself will have a limited response using Recist criteria for measuring ORR he probably found that to be true as well. "

And here is the paper, http://www.ncbi.nlm.nih.gov/pubmed/23482679
George coukos is the senoir author. Apparently you spent too much time on this board spinning what you believe than search for easy accurate information at hand.

Two subjects exhibited partial responses (PR) according to
Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
(Fig. 1A and B). Interestingly, one of these subjects progressed on
bevacizumab and metronomic cyclophosphamide prior to receiv-
ing the vaccine, but exhibited a PR afterwards. Two other sub-
jects exhibited stable disease (SD). One of these subjects entered
the trial with no evidence of disease (NED) after tertiary debulk-
ing surgery, remained in remission until end of study (EOS), and
continued to receive vaccine boosts every 4 weeks combined with
bevacizumab, remaining disease-free for 14 mo, until vaccine was
exhausted (Fig. 1C). Interestingly, this subject had previously
failed to respond to bevacizumab. Two additional exhibited pro-
gressive disease, according to RECIST 1.1.

Two PRs including 1 CR and two SDs among 6 patients. Yeah, DC-L is too weak... for you or AF. For your information, the 1 CR patient had 2 tumor recurrences with 14 month pfs for the 1st recurrence and 7 month pfs for the 2nd recurrence before entering the trial. After the vacine, the third PFS is 45 months and counting.


The UPenn then tried their own version of T cell therapy and nothing worth reporting emerged from their work after NWBO bailed this trial.

Of course, this is a small trial and bear that in your mind, NWBO longs.